The results of the use of bovhyaluronidase azoximer in the complex therapy of pelvic inflammatory disease

Abstract

The results of the use of bovhyaluronidase azoximer in the complex therapy of pelvic inflammatory disease Dobrokhotova Yu.E., Filatova L. A., Grishin I.I.Pirogov Russian National Research Medical University, Moscow Pirogov Russian National Research Medical University, Moscow Pelvic inflammatory diseases (PID) are an important gynecological problem, which leads to a violation of the reproductive function of women, in particular, the development of peritoneal adhesions. The aim of the research was to study the efficacy of Longidaza® in the complex pathogenetic therapy of PID at the basic treatment stage. Patients and Methods: 21 women of reproductive age with PID. All the women received basic treatment. The complex treatment included Longidaza® vaginal suppositories of 3000 IU per 1 suppository every 2 days, by the course № 10, then 1 suppository every 5 days (the total duration was 3 months). The patients were observed for 6 months. The effectiveness of therapy was determined by the dynamics of diagnostic criteria (clinical and laboratory), the dynamic ultrasound examination of the small pelvis organs and vessels was carried out. Results: during the observation, the patients who received complex therapy with Longidaza® restored the secretory and menstrual functions. Doppler imaging of blood circulation in the pelvic arteries showed a positive dynamics of blood flow characteristics and improvement of local microcirculation. Conclusion: the study allows us to recommend the use of Longidaza® at an early stage of treatment to improve the clinical effectiveness of the complex treatment of PID due to its anti-inflammatory, microcirculatory and antifibrotic action. The Longidaza® suppositories, as a drug form, provide the local application in gynecology, this fact is important for explaining the high effectiveness of the drug due to the peculiarities of the blood supply to the pelvic organs. Longidaza® allows to increase the effectiveness of treatment and rehabilitation of patients with PID and is recommended for using together with the basic PID therapy at an early treatment stage (according to the federal guidelines) to prevent the development of peritoneal adhesions, decrease the adhesions degree, reduce the risk of peritoneal adhesions formation and, as a consequence, a tubal and/or peritoneal factor of infertility. Key words: adhesions, inflammatory diseases, tubal peritoneal factor of infertility, bovhyaluronidase, Longidaza. For citation: Dobrokhotova Yu.E., Filatova L. A., Grishin I. I. The results of the use of bovhyaluronidase azoximer in the complex therapy of pelvic inflammatory disease // RMJ. 2018. № 2(I). P. 19–22.